Company profile: Alvotech
1.1 - Company Overview
Company description
- Provider of fully integrated biosimilar development and manufacturing, including monoclonal antibodies for immunology, oncology, and ophthalmology. Offers R&D and clinical services and worldwide commercial partnerships to expand access to biologic medicines. Employs single-use technology and Iceland’s renewable energy. Portfolio includes AVT02 (adalimumab) and AVT04 (ustekinumab), approved across multiple regions.
Products and services
- AVT02: Engineers an adalimumab biosimilar for immunology, multi-region approved in the U.S., Europe, and Canada, aligning with Alvotech’s mission to increase access to effective biologic therapies
- AVT04: Develops an ustekinumab biosimilar for immunology, regionally approved in Japan, Canada, and the EU/EEA, supporting commercialization to expand patient access to affordable biologic medicines
- Biosimilars Development and Manufacturing: Architects and fabricates biosimilars, including monoclonal antibodies for immunology, oncology, and ophthalmology, utilizing single-use manufacturing to advance and produce high-quality biologic medicines
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alvotech
Redwood Bioscience
HQ: United States
Website
- Description: Provider of precision protein-chemical engineering to develop optimized, novel biotherapeutics using site-specific modification technology to create homogenous biologic-synthetic conjugates; offering microscale perfusion-based cultivation for Pichia pastoris, E. coli recombinant proteins, CagA diagnostic proteins, and KRAS G12D recombinant protein vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redwood Bioscience company profile →
Vertex Pharmaceuticals
HQ: United States
Website
- Description: Provider of small molecule drugs for serious diseases, including cystic fibrosis medicines, and research and development of therapies for sickle cell disease, type 1 diabetes, APOL1-mediated kidney disease, pain management, and beta thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vertex Pharmaceuticals company profile →
Genkyotex
HQ: Switzerland
Website
- Description: Provider of innovative drugs and platform technology that block NOX enzymes producing oxygen radicals to treat oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy. Offerings include setanaxib and a NOX inhibitor platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genkyotex company profile →
Chronos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of age-related disease drug development, advancing SFX-01, a sulforaphane-based stable tablet for oncology and neurodevelopmental disorders; a highly selective orexin 1 receptor antagonist for addictive behaviors including binge eating disorder and alcohol use disorder; and an atypical DAT inhibitor for fatigue and narcolepsy, plus licensing and partnership collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chronos Therapeutics company profile →
AM-Pharma
HQ: The Netherlands
Website
- Description: Provider of biopharmaceutical therapeutics focused on inflammatory and infectious diseases, developing and commercializing products based on endogenous proteins, including ilofotase alfa, a recombinant alkaline phosphatase under development to prevent cardiac surgery-associated renal damage and as enzyme replacement therapy for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AM-Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alvotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alvotech
2.2 - Growth funds investing in similar companies to Alvotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alvotech
4.2 - Public trading comparable groups for Alvotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →